Packard Biosciences Postpones Offering | GenomeWeb

NEW YORK, March 29 – Packard Biosciences has indefinitely postponed a planned follow-on offering of 10 million shares of its common stock, the company said Thursday.

The offering, which the company had announced in early February, is being postponed due to the downturn in the market, said Mike Zebarth, a company spokesman. Packard has filed an amended registration with the US Securities and Exchange Commission to reflect the change of plans.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.